Показати скорочений опис матеріалу
dc.contributor.author | Artyomenko, V. | en |
dc.contributor.author | Lahoda, D. | en |
dc.contributor.author | Shapoval, V. | en |
dc.contributor.author | Mnih, L. | en |
dc.contributor.author | Domakova, N. | en |
dc.date.accessioned | 2025-01-24T06:51:58Z | |
dc.date.available | 2025-01-24T06:51:58Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | Artyomenko V., Lahoda D., Shapoval V., Mnih L., Domakova N. Polycystic Ovary Syndrome and Obesity Clinical and Laboratory Specialties: A Challenge to Fertility Preservation in Women of Reproductive Age. Тези 20-ї Міжнародної клінічної та наукової конференції з відновної репродуктивної медицини. 07-10.08.2024 Ванкувер, Канада https://iirrm.org/courses/icsc4rrm2024/lessons/e-posters-2024-abstract-presentations | en |
dc.identifier.uri | https://repo.odmu.edu.ua:443/xmlui/handle/123456789/16716 | |
dc.description.abstract | Approximately 10-18% of women of reproductive age suffer from polycystic ovary syndrome (PCOS). Women with PCOS have a high prevalence of metabolic syndrome (MS), with an incidence of up to 33%. Obesity is associated with long-term consequences such as cardiovascular disease, difficulty in conceiving and carrying a pregnancy, psychological problems, etc. Hirode et al. (2020) found that in the United States, the prevalence of obesity increases significantly with age, from 19.5% among people aged 20 to 39 years to 48.6% among people aged 60 years and older. It was also found that MS increases the risk of type 2 diabetes mellitus 5-fold and that PCOS is a significant unmodifiable risk factor for these patients. | en |
dc.language.iso | en | en |
dc.subject | polycystic ovary syndrome | en |
dc.title | Polycystic Ovary Syndrome and Obesity Clinical and Laboratory Specialties: A Challenge to Fertility Preservation in Women of Reproductive Age | en |
dc.type | Article | en |